Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: chester lee who wrote (4464)	6/5/1998 7:21:00 AM
From: Linda Kaplan	Respond to of 7041

News about the stock: Headline: (UPDATE) Zonagen Stock Continues Decline On Concerns About Impotence Drug ====================================================================== NEW YORK -(Dow Jones)- Shares of Zonagen Inc. continued to fall Thursday after trial results presented at a medical conference earlier this week cast doubt on its lead product's ability to compete with Pfizer Inc.'s blockbuster impotence pill, Viagra. At the close, Zonagen shares (ZONA), which fell 15% Wednesday, were down $4.313, or 14%, at $26.938 on Nasdaq volume of 1.9 million shares, about five times its average daily volume. The test results revealed Tuesday at the American Urological Association meeting in San Diego showed that while Zonagen's impotence pill Vasomax works and is safe, it was less effective than Viagra. Researchers noted, however, that the two drugs haven't been directly compared in studies. Scientists presented results showing that 37% to 45% of about 300 patients taking Vasomax got better erections than without the drug. Pfizer's (PFE) Viagra, by contrast, helps about 70% of impotent men. Moreover, some doctors worry that Vasomax could lower blood pressure and cause cardiovascular side effects, although this wasn't seen in the trial. In the past, Zonagen's clinical trials have been controversial. Several short sellers have attacked the company's testing as flawed. Zonagen, of the Woodlands, Texas, is collaborating with pharmaceutical giant Schering-Plough Corp. (SGP) to develop the drug and is expected to file for government marketing approval this month. The drug was approved for use in Mexico last week. -By Jennifer Fron Mauer; 201-938-5287; jennifer-fron.mauer@cor.dowjones.com Copyright (c) 1998 Dow Jones & Company, Inc. All Rights Reserved.